Literature DB >> 1918948

Evaluation of monophosphoryl lipid A (MPL) as an adjuvant. Enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPL.

R Schneerson1, A Fattom, S C Szu, D Bryla, J T Ulrich, J A Rudbach, G Schiffman, J B Robbins.   

Abstract

Concurrent injection of monophosphoryl lipid A (MPL) in saline or as an oil-in-water emulsion enhanced both the primary and secondary serum antibody responses to the capsular polysaccharide (CP) components of seven conjugates: the enhanced responses were Ag-specific. In contrast, MPL did not enhance the serum antibody response to five of the six unconjugated CP. MPL and trehalose dimycolate injected concurrently with the unconjugated Vi CP of Salmonella typhi (Vi) enhanced the serum antibody response to that Ag. MPL further enhanced the Vi antibody levels when injected with conjugates of this CP. The serum antibody responses to Pseudomonas aeruginosa exotoxin A, used as the carrier protein for the Staphylococcus aureus types 5 and 8 conjugates, were also enhanced by MPL. MPL in oil-in-water emulsion was generally more effective than when administered in saline.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1918948

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  10 in total

1.  Synthesis, characterization, and immunologic properties of detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins.

Authors:  X X Gu; C M Tsai; T Ueyama; S J Barenkamp; J B Robbins; D J Lim
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

2.  Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection.

Authors:  L O Bakaletz; B J Kennedy; L A Novotny; G Duquesne; J Cohen; Y Lobet
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

3.  Anticancer Mechanisms in Two Murine Bone Marrow-Derived Dendritic Cell Subsets Activated with TLR4 Agonists.

Authors:  Alexander Bagaev; Aleksey Pichugin; Edward L Nelson; Michael G Agadjanyan; Anahit Ghochikyan; Ravshan I Ataullakhanov
Journal:  J Immunol       Date:  2018-03-02       Impact factor: 5.422

4.  Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1.

Authors:  S Sasaki; T Tsuji; K Hamajima; J Fukushima; N Ishii; T Kaneko; K Q Xin; H Mohri; I Aoki; T Okubo; K Nishioka; K Okuda
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

5.  Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates.

Authors:  X X Gu; C M Tsai
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

6.  Abrogation of suppression of delayed hypersensitivity induced by Candida albicans-derived mannan by treatment with monophosphoryl lipid A.

Authors:  J E Domer; L G Human; G B Andersen; J A Rudbach; G L Asherson
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

7.  Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3.

Authors:  Dirk J Lefeber; Barry Benaissa-Trouw; Johannes F G Vliegenthart; Johannis P Kamerling; Wouter T M Jansen; Kees Kraaijeveld; Harm Snippe
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

8.  A TLR4-derived non-cytotoxic, self-assembling peptide functions as a vaccine adjuvant in mice.

Authors:  Anshika Tandon; Manisha Pathak; Munesh Kumar Harioudh; Sabahuddin Ahmad; Mohd Sayeed; Tayyaba Afshan; M I Siddiqi; Kalyan Mitra; Shailja M Bhattacharya; Jimut Kanti Ghosh
Journal:  J Biol Chem       Date:  2018-11-01       Impact factor: 5.157

9.  Synthetic Toll like receptor-4 (TLR-4) agonist peptides as a novel class of adjuvants.

Authors:  Arulkumaran Shanmugam; Shilpi Rajoria; Andrea L George; Abraham Mittelman; Robert Suriano; Raj K Tiwari
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240

Review 10.  Vaccine technologies: From whole organisms to rationally designed protein assemblies.

Authors:  Christopher P Karch; Peter Burkhard
Journal:  Biochem Pharmacol       Date:  2016-05-06       Impact factor: 5.858

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.